|
Date: 31 Aug 2021 (Tuesday)
Time: 9am - 10am Format: Zoom Webinar (registration is required) Hosted by: Xinyi SU, IMCB & ExCo SCSS |
|
Speaker's information
Mandeep SINGH Wilmer Eye Institute, Johns Hopkins Hospital, Boston, USA Progress and Challenges in Retinal Stem Cell Therapy for Vision Repair and Regeneration |
|
ABSTRACT
The vast majority degenerative retinal diseases that cause poor vision and blindness are currently incurable. Stem cell therapy holds promise as a potential treatment for these conditions. A substantial body of preclinical research has illuminated mechanisms of neural repair in the mammalian retina including synaptic reconnection and intercellular cytoplasmic materials transfer. Building on those findings, recently, safety and potential efficacy data have emerged from several Phase I/II clinical trials of retinal stem cell therapy. While encouraging progress has been made in cell generation and delivery methods, several reports of serious adverse events have emerged. This talk will summarize and discuss the preclinical and clinical research aspects of retinal stem cell therapy in the context of its potential to be developed into an effective treatment for retinal degenerative diseases.
BIO
Mandeep S. Singh, M.D., Ph.D., is an ophthalmologist and vitreoretinal surgeon at the Wilmer Eye Institute, Johns Hopkins Hospital. He is the Co-Director of the Genetic Eye Diseases (GEDi) Center, and a faculty member of the Stem Cells and Ocular Regenerative Medicine (STORM) Center. His research on retinal stem cell therapy has been published in PNAS, Science Translational Medicine, Nature Communications, among others. He received the Ruskell Medal in 2013 and the Bert M. Glaser MD Award for Innovative Research in Retina in 2019. He is a Hartwell Investigator, a member of the Club Jules Gonin and Macula Society, and currently leads a federally-funded translational research program on retinal stem cell therapy
The vast majority degenerative retinal diseases that cause poor vision and blindness are currently incurable. Stem cell therapy holds promise as a potential treatment for these conditions. A substantial body of preclinical research has illuminated mechanisms of neural repair in the mammalian retina including synaptic reconnection and intercellular cytoplasmic materials transfer. Building on those findings, recently, safety and potential efficacy data have emerged from several Phase I/II clinical trials of retinal stem cell therapy. While encouraging progress has been made in cell generation and delivery methods, several reports of serious adverse events have emerged. This talk will summarize and discuss the preclinical and clinical research aspects of retinal stem cell therapy in the context of its potential to be developed into an effective treatment for retinal degenerative diseases.
BIO
Mandeep S. Singh, M.D., Ph.D., is an ophthalmologist and vitreoretinal surgeon at the Wilmer Eye Institute, Johns Hopkins Hospital. He is the Co-Director of the Genetic Eye Diseases (GEDi) Center, and a faculty member of the Stem Cells and Ocular Regenerative Medicine (STORM) Center. His research on retinal stem cell therapy has been published in PNAS, Science Translational Medicine, Nature Communications, among others. He received the Ruskell Medal in 2013 and the Bert M. Glaser MD Award for Innovative Research in Retina in 2019. He is a Hartwell Investigator, a member of the Club Jules Gonin and Macula Society, and currently leads a federally-funded translational research program on retinal stem cell therapy